Profile
Sector:
HealthcareIndustry:
Drug Manufacturers - GeneralCountry:
DenmarkIPO:
30 April 1981Website:
http://www.novonordisk.comNext earnings report:
06 November 2024Last dividends:
16 August 2024Next dividends:
N/APrice
pre-market | 57 min agoAnalysts recommendations
Institutional Ownership
NVO Latest News
Novo Nordisk said on Friday its weight-loss drug Wegovy met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.
Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3)1. Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised people at 72 weeks.
All doses of Novo Nordisk's weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the FDA's drug shortage database. It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.
In the latest trading session, Novo Nordisk (NVO) closed at $112.46, marking a -0.82% move from the previous day.
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bagsværd, Denmark, 28 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.
Novo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, according to a new analysis of electronic health records. The findings suggest that Ozempic and other GLP-1 treatments could potentially delay or prevent the memory-robbing condition in patients with diabetes.
Novo Nordisk (NVO) closed at $116.47 in the latest trading session, marking a -0.73% move from the prior day.
Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting heart-related risks in patients, state of the weight-loss drugs market, and more.
What type of business is Novo Nordisk A/S?
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
What sector is Novo Nordisk A/S in?
Novo Nordisk A/S is in the Healthcare sector
What industry is Novo Nordisk A/S in?
Novo Nordisk A/S is in the Drug Manufacturers - General industry
What country is Novo Nordisk A/S from?
Novo Nordisk A/S is headquartered in Denmark
When did Novo Nordisk A/S go public?
Novo Nordisk A/S initial public offering (IPO) was on 30 April 1981
What is Novo Nordisk A/S website?
https://www.novonordisk.com
Is Novo Nordisk A/S in the S&P 500?
No, Novo Nordisk A/S is not included in the S&P 500 index
Is Novo Nordisk A/S in the NASDAQ 100?
No, Novo Nordisk A/S is not included in the NASDAQ 100 index
Is Novo Nordisk A/S in the Dow Jones?
No, Novo Nordisk A/S is not included in the Dow Jones index
When was Novo Nordisk A/S the previous earnings report?
No data
When does Novo Nordisk A/S earnings report?
The next expected earnings date for Novo Nordisk A/S is 06 November 2024